BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28411246)

  • 1. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
    Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
    Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
    Hagström E; James SK; Bertilsson M; Becker RC; Himmelmann A; Husted S; Katus HA; Steg PG; Storey RF; Siegbahn A; Wallentin L;
    Eur Heart J; 2016 Apr; 37(16):1325-33. PubMed ID: 26417057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
    Alfredsson J; Neely B; Neely ML; Bhatt DL; Goodman SG; Tricoci P; Mahaffey KW; Cornel JH; White HD; Fox KA; Prabhakaran D; Winters KJ; Armstrong PW; Ohman EM; Roe MT;
    Heart; 2017 Aug; 103(15):1168-1176. PubMed ID: 28381584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
    J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Jackson LR; Piccini JP; Cyr DD; Roe MT; Neely ML; Martinez F; Lüscher TF; Lopes RD; Winters KJ; White HD; Armstrong PW; Fox KA; Prabhakaran D; Bhatt DL; Magnus Ohman E; Corbalán R
    Clin Cardiol; 2016 Sep; 39(9):497-506. PubMed ID: 27468086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
    Ducrocq G; Schulte PJ; Becker RC; Cannon CP; Harrington RA; Held C; Himmelmann A; Lassila R; Storey RF; Sorbets E; Wallentin L; Steg PG
    EuroIntervention; 2015 Nov; 11(7):737-45. PubMed ID: 25254357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
    Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
    Cuisset T; Cayla G; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Morange PE; Alessi MC; Bonnet JL
    EuroIntervention; 2009 Aug; 5(3):325-9. PubMed ID: 19736156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
    Cornel JH; Ohman EM; Neely B; Jakubowski JA; Bhatt DL; White HD; Ardissino D; Fox KA; Prabhakaran D; Armstrong PW; Erlinge D; Tantry US; Gurbel PA; Roe MT
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27815268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
    Marquis-Gravel G; Neely ML; Valgimigli M; Costa F; Van Klaveren D; Altner R; Bhatt DL; Armstrong PW; Fox KAA; White HD; Ohman EM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006582. PubMed ID: 32862694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
    Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
    JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
    Smith JG; Wieloch M; Koul S; Braun OÖ; Lumsden J; Rydell E; Ohman J; Scherstén F; Svensson PJ; van der Pals J
    EuroIntervention; 2012 Oct; 8(6):672-8. PubMed ID: 23086784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Ducrocq G; Schulte PJ; Budaj A; Cornel JH; Held C; Himmelmann A; Husted S; Storey RF; Cannon CP; Becker RC; James SK; Katus HA; Lopes RD; Sorbets E; Wallentin L; Steg PG
    Am Heart J; 2017 Apr; 186():91-99. PubMed ID: 28454837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.